Cogstate (ASX:CGS) has signed a contract worth US$1.2 million for its computerised cognition tests to be used in a Phase II clinical trial of patients with Alzheimer’s disease.
This takes the total value of clinical trials sales contracts signed since 1 July 2015 to US$2.3 million.
It already has contracted revenue of A$13 million for FY2016 and A$7 million for FY2017.
Cogstate is reliant on the volume of clinical trials rather than their success as its key revenue drive.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
-0.030(1.74%) |
Mkt cap ! $288.6M | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.72 | $1.69 | $23.72K | 13.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 591 | $1.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.71 | 2290 | 3 |
View Market Depth
| Last trade - 12.16pm 16/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |